Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company is conducting a Phase ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly (NYSE:LLY) shares rose about 2% on early Thursday after the company said a pivotal study for its experimental ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks.

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Art Hogan, chief market strategist at B. Riley Wealth, joins BNN Bloomberg to discuss the outlook on the markets and provide ...

Oct 14 (Reuters) - Eli Lilly & Co (LLY.N), opens new tab on Wednesday said other trials of its experimental coronavirus antibody therapy remain on track after a government-run study testing the ...